|
1
|
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
|
N Engl J Med
|
1998
|
14.40
|
|
2
|
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
|
Gastroenterology
|
2001
|
8.09
|
|
3
|
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
|
N Engl J Med
|
1998
|
6.23
|
|
4
|
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
|
N Engl J Med
|
2000
|
3.74
|
|
5
|
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
|
Hepatology
|
2001
|
3.02
|
|
6
|
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial.
|
Ann Intern Med
|
1997
|
2.69
|
|
7
|
Right lobe living donor liver transplantation.
|
Transplantation
|
1999
|
2.31
|
|
8
|
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.
|
Liver Transpl Surg
|
1997
|
2.16
|
|
9
|
The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts.
|
Gastroenterology
|
1997
|
1.74
|
|
10
|
Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review.
|
Radiographics
|
1993
|
1.68
|
|
11
|
Selection and outcome of living donors for adult to adult right lobe transplantation.
|
Transplantation
|
2000
|
1.57
|
|
12
|
The hematologic consequences of transjugular intrahepatic portosystemic shunts.
|
Hepatology
|
1996
|
1.55
|
|
13
|
Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.
|
Liver Transpl
|
2001
|
1.45
|
|
14
|
A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
|
Aliment Pharmacol Ther
|
2004
|
1.45
|
|
15
|
Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation.
|
Transplantation
|
2000
|
1.42
|
|
16
|
Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.
|
Hepatology
|
1994
|
1.35
|
|
17
|
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss.
|
Am J Surg
|
1995
|
1.33
|
|
18
|
Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy.
|
Gastroenterology
|
1996
|
1.28
|
|
19
|
Emergency adult to adult living donor liver transplantation for fulminant hepatic failure.
|
Transplantation
|
2000
|
1.25
|
|
20
|
Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests.
|
J Clin Microbiol
|
2001
|
1.22
|
|
21
|
Metformin-induced acute hepatitis.
|
Am J Med
|
1998
|
1.01
|
|
22
|
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.
|
Transplantation
|
1998
|
1.00
|
|
23
|
Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation.
|
Am J Gastroenterol
|
1999
|
0.97
|
|
24
|
Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study.
|
Radiology
|
2000
|
0.95
|
|
25
|
Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
|
Hepatology
|
1999
|
0.91
|
|
26
|
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
|
Aliment Pharmacol Ther
|
2008
|
0.91
|
|
27
|
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.
|
J Viral Hepat
|
2013
|
0.90
|
|
28
|
Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
|
Aliment Pharmacol Ther
|
2006
|
0.90
|
|
29
|
Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
|
Aliment Pharmacol Ther
|
2008
|
0.90
|
|
30
|
Emergency portacaval shunt for control of hemorrhage from a parenchymal fracture after adult-to-adult living donor liver transplantation.
|
Transplantation
|
2000
|
0.90
|
|
31
|
A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation.
|
Transplantation
|
1998
|
0.88
|
|
32
|
The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.
|
Aliment Pharmacol Ther
|
2008
|
0.87
|
|
33
|
Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt.
|
Aliment Pharmacol Ther
|
2007
|
0.84
|
|
34
|
Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience.
|
Transplant Proc
|
2007
|
0.84
|
|
35
|
Nonsteroidal antiinflammatory drugs and gallstone disease: will an aspirin a day keep the gallstones away?
|
Am J Gastroenterol
|
1998
|
0.83
|
|
36
|
Results with percutaneous transjugular intrahepatic portosystemic stent-shunts for control of variceal hemorrhage in patients awaiting liver transplantation.
|
Transplant Proc
|
1993
|
0.82
|
|
37
|
The impact of a positive crossmatch upon outcome after liver transplantation.
|
Transplantation
|
1996
|
0.82
|
|
38
|
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
|
J Viral Hepat
|
2012
|
0.82
|
|
39
|
Benign recurrent intrahepatic cholestasis.
|
Clin Liver Dis
|
1999
|
0.81
|
|
40
|
Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease.
|
Haemophilia
|
2007
|
0.81
|
|
41
|
Primary hepatocellular carcinoma after orthotopic liver transplantation for chronic hepatitis B infection.
|
Ann Intern Med
|
1991
|
0.81
|
|
42
|
Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma-derived model.
|
Lab Invest
|
1993
|
0.80
|
|
43
|
Adenosine rinse in human orthotopic liver transplantation: results of a randomized, double-blind trial.
|
Int J Surg Investig
|
1999
|
0.80
|
|
44
|
Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation.
|
Clin Genet
|
2004
|
0.80
|
|
45
|
Human gallbladder mucosal function: effects on intraluminal fluid and lipid composition in health and disease.
|
Dig Dis Sci
|
1998
|
0.79
|
|
46
|
Bleeding gastroesophageal varices.
|
Semin Liver Dis
|
1993
|
0.78
|
|
47
|
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
|
Aliment Pharmacol Ther
|
2007
|
0.78
|
|
48
|
Protein dissociation from DNA in model systems and chromatin.
|
Nucleic Acids Res
|
1978
|
0.77
|
|
49
|
Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation.
|
Transplant Proc
|
1993
|
0.77
|
|
50
|
Effect of NSAIDs on gallbladder bile composition.
|
Dig Dis Sci
|
1995
|
0.77
|
|
51
|
Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
|
Aliment Pharmacol Ther
|
2007
|
0.76
|
|
52
|
Treatment of fulminant hepatic failure with intravenous prostaglandin E1.
|
Liver Transpl Surg
|
1998
|
0.76
|
|
53
|
Altered bicarbonate reabsorption in the pancreas of reserpine-treated rabbits--a model for cystic fibrosis.
|
Pediatr Res
|
1983
|
0.76
|
|
54
|
An atypical presentation for primary sclerosing cholangitis.
|
Dig Dis Sci
|
1997
|
0.75
|
|
55
|
The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis.
|
Hepatology
|
1999
|
0.75
|
|
56
|
Can anticoagulation enhance TIPS patency?
|
Hepatology
|
1996
|
0.75
|
|
57
|
Flumazenil for hepatic coma: the elusive wake-up call?
|
Gastroenterology
|
1994
|
0.75
|
|
58
|
The evolving genetics of hepatitis C virus: separating the wheat from the chaff.
|
Dig Dis
|
1997
|
0.75
|
|
59
|
Pancreatic function in the reserpinized rabbit--a model for cystic fibrosis. I. Effect of secretin.
|
Pediatr Res
|
1982
|
0.75
|
|
60
|
Oxaprozin-induced fulminant hepatitis.
|
Ann Pharmacother
|
1994
|
0.75
|
|
61
|
In vivo studies of biliary ceftriaxone excretion and solubility in guinea pig hepatic bile.
|
J Lab Clin Med
|
1992
|
0.75
|
|
62
|
Transjugular intrahepatic portosystemic shunt: a medical perspective.
|
Dig Dis
|
1996
|
0.75
|
|
63
|
Variations in pigment and carbohydrate content of gallbladder bile affect accurate quantitation of total protein when using the fluorescamine method.
|
Scand J Gastroenterol
|
1997
|
0.75
|
|
64
|
Induction with OKT3 and prostaglandin E1 in liver transplantation.
|
Transplant Sci
|
1994
|
0.75
|
|
65
|
Natural history of post-transfusion hepatitis: the wolf in sheep's clothing.
|
Am J Gastroenterol
|
1993
|
0.75
|